Indicated for: cancer
Route of administration: infusion / intravenous
Substance: vincristine (antineoplastic agent)
ATC: L01CA02 (Antineoplastic and immunomodulating agents | Plant alkaloids and other natural products | Vinca alkaloids and analogues)
Vincristine is a chemotherapy medication used for the treatment of various types of cancer, including acute lymphoblastic leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, and Ewing's sarcoma. It belongs to the vinca alkaloid class and works by inhibiting microtubule formation, leading to the arrest of cell division and tumor cell death.
Vincristine is administered intravenously, usually once a week, and the dosage is adjusted based on body weight and patient response. Treatment is conducted under the supervision of an oncologist, and patients are monitored for signs of toxicity.
Common side effects include peripheral neuropathy, constipation, hair loss, nausea, and fatigue. In rare cases, severe adverse reactions such as liver function impairment or bone marrow depression may occur.
Vincristine is an essential component of many chemotherapy regimens, helping to reduce tumor size and improve survival rates in cancer patients.